Clinical Commander

All dossiers
cardio.cardiogenic-shock.takotsubo-lvot-obstruction.v1

Cardiogenic shock — Takotsubo with dynamic LVOT obstruction (SAM-mediated)

cardiologyacuteadultacuteinpatienttransitionoutpatient
Start encounter →Print handoutPRODUCTION

Phase E sub-variant of cardio.cardiogenic-shock.takotsubo.v1 — narrowed to the 15–25% of Takotsubo patients who develop DYNAMIC LVOT OBSTRUCTION from septal hyperkinesis paired with apical akinesis (Bernoulli/Venturi effect → SAM of mitral valve → subaortic gradient + posteriorly directed MR jet). Per Templin NEJM 2015 PMID 26332547 InterTAK registry + Lyon 2016 ESC HFA position statement (definitive source). Hemodynamics OPPOSITE to typical Takotsubo: PRELOAD-DEPENDENT, AFTERLOAD-RESPONSIVE. GIVE: IV fluids + phenylephrine (pure α) + esmolol (β1-blocker). The one Takotsubo subset where β-blocker is the right answer despite the general AVOID rule. AVOID: inotropes (worsen septal hyperkinesis); diuretics (worsen preload); nitrates (worsen preload + afterload); IABP (afterload reduction worsens obstruction — same reasoning as HOCM contraindication). Diagnosis: TTE/TEE with LVOT pulsed/continuous Doppler — gradient ≥30 mmHg at rest or ≥50 mmHg with provocation; SAM of anterior mitral leaflet; posteriorly directed MR jet; apical akinesis + basal hyperkinesis ratio is pathognomonic. Mandatory emergency angiography to rule out obstructive CAD per Ghadri 2018 InterTAK criteria. Recovery typically 1–4 wks (faster than non-LVOT Takotsubo); gradient resolves with apical recovery as septal hyperkinesis normalizes. Long-term β-blocker maintenance (carvedilol/metoprolol succinate) is more reasonable in this subset than general Takotsubo per Lyon 2016 — recurrence-prevention rationale. Mechanistic parallel to HOCM acute management (Maron AHA 2020) — same INVERTED hemodynamic principles. Failure to recognize subtype is the primary preventable cause of mortality (inotrope/IABP errors). Status INTEGRATED until terminology + RxNav-validated drug codes are reconciled. Authored 2026-05-15 by shard-06-cardio-acute as Phase E wave 15 etiology sub-variant.

Entry points (4)

  • imaging
    Bedside echo: apical ballooning + basal hyperkinesis + LVOT gradient ≥30 mmHg at rest (or ≥50 mmHg with provocation) + SAM of mitral valve — Takotsubo with dynamic LVOT obstruction
    echo_apical_ballooning_with_lvot_gradient
  • imaging
    TTE/TEE: systolic anterior motion of anterior mitral leaflet + posteriorly directed MR jet in patient with confirmed Takotsubo apical ballooning
    sam_with_posterior_mr_jet_after_takotsubo_diagnosis
  • history
    Patient with Takotsubo CS deteriorating paradoxically after inotrope/IABP initiation (drop in BP + rising lactate) — diagnostic clue to occult LVOT obstruction; OBTAIN STAT echo with Doppler
    shock_worsening_after_inotropes_in_takotsubo
  • history
    Postmenopausal female (~90% Takotsubo predominance) presenting with shock + new harsh systolic murmur (mistaken for AS or papillary rupture) + apical akinesia → LVOT-obstruction Takotsubo
    severe_emotional_or_physical_stressor_with_systolic_murmur

Required inputs (13)

  • agerequired
    demographic • used at CONTEXT
    Postmenopausal female ~90% predominant; informs risk-stratification anchor
  • sex_female_postmenopausalrequired
    demographic • used at CONTEXT
    InterTAK registry — ~90% female, ~80% age >50; LVOT-subtype rate within Takotsubo ~15–25% (Templin NEJM 2015 PMID 26332547)
  • sbprequired
    vital • used at RED_FLAGS
    Hypotension severity gates fluid + phenylephrine titration; SBP often paradoxically WORSE with inotropes — diagnostic clue
  • hrrequired
    vital • used at CONTEXT
    Tachycardia worsens LVOT obstruction (less diastolic filling time → smaller LV cavity → worse gradient); esmolol-titration gate
  • lactaterequired
    lab • used at RISK_STRATIFICATION
    SCAI 2022 staging + LVOT-subtype response: lactate often improves rapidly with subtype-appropriate therapy (fluids + phenylephrine + esmolol), worsens with inotrope error
  • creatininerequired
    lab • used at CONTEXT
    End-organ damage marker; renal function gates DOAC dosing for mural-thrombus prophylaxis
  • troponinrequired
    lab • used at INITIAL_WORKUP
    Modest rise typical Takotsubo discordance; helps confirm diagnosis (vs MI mimic)
  • bnp_ntprobnprequired
    lab • used at INITIAL_WORKUP
    Markedly elevated; LVOT obstruction adds volume/pressure load → BNP often disproportionately high
  • echo_with_lvot_dopplerrequired
    imaging • used at INITIAL_WORKUP
    LVOT pulsed/continuous Doppler — gradient ≥30 mmHg at rest OR ≥50 mmHg with provocation defines obstructive variant; SAM of MV on 2D; posteriorly directed MR jet on color
  • ecgrequired
    imaging • used at INITIAL_WORKUP
    Diffuse T-wave inversion + QT prolongation typical; rule out STEMI mimic; QT often >500 ms (torsades risk)
  • cor_angiorequired
    imaging • used at BRANCHING_WORKUP
    Mandatory rule-out of obstructive CAD per Ghadri 2018 InterTAK criteria; LV gram confirms apical ballooning
  • tee_for_sam_confirmation
    imaging • used at BRANCHING_WORKUP
    TEE preferred over TTE if window suboptimal — definitive for SAM, MR mechanism, and gradient localization
  • recent_stressor_emotional_or_physicalrequired
    history • used at CONTEXT
    Trigger identification — physical-stressor Takotsubo has higher mortality (Templin NEJM 2015)

12-phase flow (11)

  1. 1FRAME
    Confirm Takotsubo with LVOT obstruction and shock — apical ballooning + basal hyperkinesis + LVOT gradient ≥30 mmHg + SAM + shock physiology; this is a SUB-variant of takotsubo CS with INVERTED management physiology
    inputs: echo_with_lvot_doppler, cor_angio
    advance: LVOT-obstruction Takotsubo confirmed + shock overlay documented
  2. 2ENTRY
    CS team activation; emergency cath to rule out obstructive CAD (mandatory per InterTAK 2018); STAT echo with Doppler for LVOT gradient + SAM assessment
    inputs: sbp, lactate
    advance: CS team activated + obstructive CAD excluded + LVOT gradient measured
  3. 3CONTEXT
    Trigger identification, comorbidities, baseline meds (current inotrope/IABP exposure may have worsened the picture — withdraw immediately), code status
    inputs: hr, creatinine, recent_stressor_emotional_or_physical
    advance: Context complete + iatrogenic inotrope/IABP exposure withdrawn if present
  4. 4RED_FLAGS
    Inotrope-error worsening (paradoxical BP drop after dobutamine/milrinone/NE — STOP and switch to phenylephrine + esmolol); IABP-error worsening (afterload reduction worsens gradient — REMOVE); refractory MR with shock; mural thrombus from apical akinesia (anticoagulate if EF<35); torsades from QT prolongation
    inputs: sbp
    actions: cardiogenic_shock, cardiac_tamponade
    advance: Iatrogenic worseners removed + subtype-appropriate therapy started
  5. 5INITIAL_WORKUP
    ECG (T-wave inversion + QT prolongation), STAT TTE/TEE with LVOT Doppler (gradient + SAM + MR mechanism), troponin (modest), BNP (markedly elevated), BMP, lactate, ABG, CXR; MERLIN-TT score for prognosis
    inputs: ecg, echo_with_lvot_doppler, troponin, bnp_ntprobnp, lactate
    actions: cardiogenic_shock, panel.cardiac, panel.renal, panel.abg
    advance: Diagnosis confirmed + LVOT gradient quantified + SAM documented
  6. 6BRANCHING_WORKUP
    Emergency coronary angiography mandatory (rule out obstructive CAD per InterTAK); TEE if TTE window suboptimal — definitive for SAM and MR mechanism; cardiac MRI if cath ambiguous (T2 edema + ABSENT LGE)
    inputs: cor_angio
    advance: Obstructive CAD ruled out + LVOT mechanism + MR mechanism confirmed
  7. 7RISK_STRATIFICATION
    MERLIN-TT scoring (Ghadri 2018); SCAI 2022 stage; CardShock prognosis (Harjola EHJ 2015 PMID 26333869); LVOT-subtype-specific: gradient severity (>50 vs >100 mmHg) and MR severity drive escalation thresholds
    inputs: sbp, lactate, troponin
    advance: Risk stratified
  8. 8TREATMENT
    PRELOAD: IV crystalloid bolus 250–500 mL repeated until gradient drops or pulmonary edema develops. AFTERLOAD: phenylephrine 40–360 µg/min (pure α — no inotropy). HR/INOTROPY: esmolol 500 µg/kg bolus → 50–200 µg/kg/min (slows HR, reduces septal hyperkinesis). AVOID: inotropes (dobutamine/milrinone/NE — worsen gradient); diuretics (worsen preload); nitrates (worsen preload + afterload); IABP (worsens obstruction); aggressive afterload-reducing MCS. Anticoagulate if EF<35 + apical akinesia (mural thrombus prevention; warfarin INR 2-3 or apixaban 5 mg BID × 3 mo per AHA 2022 Class IIa LV thrombus consensus extrapolation)
    inputs: sbp, lactate
    actions: cardiogenic_shock
    advance: Subtype-inverted hemodynamic regimen running + iatrogenic worseners excluded + anticoagulation decision documented
  9. 9DISPOSITION
    CICU at advanced-HF center for LVOT-subtype expertise; psych evaluation if emotional stressor; cardiothoracic surgery awareness for refractory MR (rare surgical mitral intervention)
    advance: Disposition assigned + advanced-HF + cardiothoracic teams aware
  10. 10MONITORING
    A-line, central line, lactate clearance, urine output, telemetry (QT prolongation + torsades watch), SERIAL ECHO q12h with LVOT gradient measurement (recovery is faster than non-LVOT subtype — gradient resolves within 1–2 wks as apical akinesis recovers)
    inputs: lactate
    actions: panel.cardiac, panel.renal
    advance: Monitoring + reassessment cadence set
  11. 11FOLLOWUP
    Repeat echo at 1–4 wks to confirm complete LVOT gradient resolution + LV recovery (faster than non-LVOT Takotsubo); psych follow-up; long-term β-blocker (carvedilol/metoprolol succinate) is more reasonable in this subset given LVOT-recurrence risk than in general Takotsubo (Lyon 2016 ESC HFA position favors continued β-blocker in LVOT-subtype recovery); recurrence ~5–10% over follow-up
    advance: Recovery echo + psych follow-up booked + β-blocker maintenance plan documented